tbuckley/cabot-search huggingface dataset:
Postoperative Myocardial Infarction
Authors: S BAER, F NAKHJAVAN, M KAJANI
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Combining Gene Expression Profiling and Artificial Intelligence to Diagnose B-Cell Non-Hodgkin Lymphoma
Authors: Victor Bobée, Fanny Drieux, Vinciane Marchand, Vincent Sater, Liana Veresezan, Jean-Michel Picquenot, Pierre-Julien Viailly, Marie-delphine Lanic, Mathieu Viennot, Elodie Bohers, Lucie Oberic, Christiane Copie-Bergman, Thierry Jo Molina, Philippe Gaulard, Corinne Haioun, Gilles A. Salles, Herve Tilly, Fabrice Jardin, Philippe Ruminy
Journal: Blood (2019)
Incidence of Second Primary Malignancies and Peripheral Sensory Neuropathy in Patients with Multiple Myeloma Receiving Daratumumab Containing Regimen
Authors: Thura Win Htut, Donald P. Quick, Myint Aung Win, Sriman Swarup, Anita Sultan, Somedeb Ball, Ei Moe Phyu, Nyein Htway Yu, Myat Min Han, Yin Mon Myat, Fred Hardwicke, Nicholas D'Cunha, Sanjay Awasthi, Kyaw Zin Thein
Journal: Blood (2019)
Ten-Year Follow-up of Patients with Chronic Myeloid Leukemia Treated with Nilotinib in First-Line: Final Results of the Gimema CML 0307 Trial
Authors: Gabriele Gugliotta, Fausto Castagnetti, Massimo Breccia, Luciano Levato, Tamara Intermesoli, Mariella D'adda, Marzia Salvucci, Fabio Stagno, Giovanna Rege Cambrin, Mario Tiribelli, Bruno Martino, Monica Bocchia, Elena Trabacchi, Francesco Cavazzini, Ferdinando Porretto, Federica Sorà, Giovanni Caocci, Francesco Albano, Giovanni Martinelli, Simona Soverini, Robin Foà, Fabrizio Pane, Michele Cavo, Giuseppe Saglio, Michele Baccarani, Gianantonio Rosti
Journal: Blood (2019)
Acute adrenal crisis precipitated by thyroxine.
Authors: J Davis, M Sheppard
Journal: BMJ (1986)

At operation for small bowel intussusception, a 26-year-old man was found to have an enlarged liver and spleen. Subsequent investigations suggested bile passage infection associated with numerous intrahepatic gall-stones but symptomatic cholangitis did not present until 5 months later. Retrograde cholangiography showed cavernous ectasia of the bile ducts which contained gall-stones.
Expanding the Scope of Geriatric Assessment for the Management of Cancer in Older Adults
Authors: Laura Biganzoli, Amelia McCartney, Nicolò Matteo Luca Battisti
Journal: JAMA Oncology (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Abstract 19075: In-hospital Pharmacological Prophylaxis and Outcomes for Venous Thromboembolism After Hip and Knee Replacements in Older Adults
Authors: Darae Ko, Alok Kapoor, Adam Rose, Amresh Hanchate, Donald Miller, Michael Winter, Joseph Palmisano, Lori Henault, Yorghos Tripodis, Anita Karcz, Elaine Hylek
Journal: Circulation (2017)

Background: Venous thromboembolism (VTE) after total hip and knee replacement (THR, TKR) is a major patient safety threat. We sought to report trends in the selection of prophylaxis agents during t...
STAT3-Induced Gli1 Promotes the Differentiation and Maturation of Myelofibrosis Fibrocytes
Authors: Taghi Manshouri, Ivo Veletic, Ying Zhang, Joseph E. Bove, Ping Li, David M. Harris, Zhiming Liu, Evan N. Cohen, Srdan Verstovsek, Zeev E. Estrov
Journal: Blood (2019)
Serum Albumin Is an Independent Factor Predicting Survival in Patients with Peripheral T Cell Lymphoma: A Multi-Institutional Study from the Latin American Working Group for Lymphomas (GELL)
Authors: Henry Idrobo, Brady E. Beltrán, Luis Villela M, Marialejandra Torres Viera, Victoria Otero, Lorena Fiad, Camila Peña, Denisse A. Castro, Yesenia M. Huerta- Collado, Sally Rose Paredes, Ivan Perdomo, Pilar León, Christine Rojas, Virginia Abello, Monica Osuna Pérez, Juan Esteban Garcia-Robledo, Luis E Malpica Castillo, Eduardo Sotomayor, Jorge J. Castillo
Journal: Blood (2019)
SCIDOT-52. IN SITU DELIVERY OF TUMOR TREATING FIELDS THERAPY IN GLIOBLASTOMA PATIENTS
Authors: Jeffrey Arle, Eric Wong, Anders Korshoej, Socrates Dokos, Ze’ev Bomzon, Kristen Carlson
Journal: Neuro-Oncology (2019)

Abstract The efficacy of Tumor-Treating Fields (TTFields) rests on the result of a large-scale clinical trial that demonstrated an increase in the survival of newly diagnosed glioblastoma patients when combined with temozolomide chemotherapy. Overall survival now extends to over 60 months in some of our patients when dexamethasone, which we suspected of interference with TTFields effects, is replaced with celecoxib to control tumor-associated inflammation. The transcranial method of delivering TTFields has not changed in light of ongoing advances in deep brain stimulation (DBS) and transcranial electric stimulation (TES), notably that the resistivity of the skull is the principle obstacle to placing therapeutic electric field strength of 2 V/cm into target tumor sites and variation in skull thickness is the main difference in TES efficiency across individuals. Realistic human head finite element modeling (FEM) predicted that surgical craniectomy beneath TTFields’ electrodes would enhance field strength at target tumor sites. Here we show that 2 V/cm can be reliably delivered to tumor sites using minimally-invasive DBS cylindrical leads or ribbon electrode arrays, pre- or post-resection. Two objections arise to the in situ method: 1) Will TTFields stimulate axons in situ? 2) Will field strength exceed safety limits for cell damage? Neural stimulation modeling and experiments show that TTFields’ frequency of 200 kHz, 1–3 orders of magnitude higher than ion channel time constants, is too high to stimulate them. Furthermore, 2 V/cm is well below cell damage limits of 700 V/mm. Thus we propose a new delivery method to improve tumor control in glioblastoma patients and to provide valuable information on TTFields’ effects via cell studies using in situ electric fields at 200 kHz.
A Phase I-II Study of Ruxolitinib (INCB18424) for Patients with Chronic Myeloid Leukemia with Minimal Residual Disease While on Therapy with Imatinib
Authors: Veronica A Guerra, Hagop M. Kantarjian, Gautam M. Borthakur, Srdan Verstovsek, Allison Pike, Farhad Ravandi, Elias Jabbour, Jorge E. Cortes
Journal: Blood (2019)
Defective glycosylation and multisystem abnormalities characterize the primary immunodeficiency XMEN disease
Authors: Juan C. Ravell, Mami Matsuda-Lennikov, Samuel D. Chauvin, Juan Zou, Matthew Biancalana, Sally J. Deeb, Susan Price, Helen C. Su, Giulia Notarangelo, Ping Jiang, Aaron Morawski, Chrysi Kanellopoulou, Kyle Binder, Ratnadeep Mukherjee, James T. Anibal, Brian Sellers, Lixin Zheng, Tingyan He, Alex B. George, Stefania Pittaluga, Astin Powers, David E. Kleiner, Devika Kapuria, Marc Ghany, Sally Hunsberger, Jeffrey I. Cohen, Gulbu Uzel, Jenna Bergerson, Lynne Wolfe, Camilo Toro, William Gahl, Les R. Folio, Helen Matthews, Pam Angelus, Ivan K. Chinn, Jordan S. Orange, Claudia M. Trujillo-Vargas, Jose Luis Franco, Julio Orrego-Arango, Sebastian Gutiérrez-Hincapié, Niraj Chandrakant Patel, Kimiyo Raymond, Turkan Patiroglu, Ekrem Unal, Musa Karakukcu, Alexandre G.R. Day, Pankaj Mehta, Evan Masutani, Suk S. De Ravin, Harry L. Malech, Grégoire Altan-Bonnet, V. Koneti Rao, Matthias Mann, Michael J. Lenardo
Journal: Journal of Clinical Investigation (2019)

X-linked immunodeficiency with magnesium defect, EBV infection, and neoplasia (XMEN) disease are caused by deficiency of the magnesium transporter 1 (MAGT1) gene. We studied 23 patients with XMEN, 8 of whom were EBV naive. We observed lymphadenopathy (LAD), cytopenias, liver disease, cavum septum pellucidum (CSP), and increased CD4-CD8-B220-TCRαβ+ T cells (αβDNTs), in addition to the previously described features of an inverted CD4/CD8 ratio, CD4+ T lymphocytopenia, increased B cells, dysgammaglobulinemia, and decreased expression of the natural killer group 2, member D (NKG2D) receptor. EBV-associated B cell malignancies occurred frequently in EBV-infected patients. We studied patients with XMEN and patients with autoimmune lymphoproliferative syndrome (ALPS) by deep immunophenotyping (32 immune markers) using time-of-flight mass cytometry (CyTOF). Our analysis revealed that the abundance of 2 populations of naive B cells (CD20+CD27-CD22+IgM+HLA-DR+CXCR5+CXCR4++CD10+CD38+ and CD20+CD27-CD22+IgM+HLA-DR+CXCR5+CXCR4+CD10-CD38-) could differentially classify XMEN, ALPS, and healthy individuals. We also performed glycoproteomics analysis on T lymphocytes and show that XMEN disease is a congenital disorder of glycosylation that affects a restricted subset of glycoproteins. Transfection of MAGT1 mRNA enabled us to rescue proteins with defective glycosylation. Together, these data provide new clinical and pathophysiological foundations with important ramifications for the diagnosis and treatment of XMEN disease.
Somatic Mutations and Genome Stability Maintenance in Clonal Coral Colonies
Authors: Elora H López, Stephen R Palumbi
Journal: Molecular Biology and Evolution (2019)

One challenge for multicellular organisms is maintaining genome stability in the face of mutagens across long life spans. Imperfect genome maintenance leads to mutation accumulation in somatic cells, which is associated with tumors and senescence in vertebrates. Colonial reef-building corals are often large, can live for hundreds of years, rarely develop recognizable tumors, and are thought to convert somatic cells into gamete producers, so they are a pivotal group in which to understand long-term genome maintenance. To measure rates and patterns of somatic mutations, we analyzed transcriptomes from 17 to 22 branches from each of four Acropora hyacinthus colonies, determined putative single nucleotide variants, and verified them with Sanger resequencing. Unlike for human skin carcinomas, there is no signature of mutations caused by UV damage, indicating either higher efficiency of repair than in vertebrates, or strong sunscreen protection in these shallow water tropical animals. The somatic mutation frequency per nucleotide in A. hyacinthus is on the same order of magnitude (10-7) as noncancerous human somatic cells, and accumulation of mutations with age is similar. Loss of heterozygosity variants outnumber gain of heterozygosity mutations ∼2:1. Although the mutation frequency is similar in mammals and corals, the preponderance of loss of heterozygosity changes and potential selection may reduce the frequency of deleterious mutations in colonial animals like corals. This may limit the deleterious effects of somatic mutations on the coral organism as well as potential offspring.
A Meta-Analysis on the Efficacy of Thrombopoietin (TPO) Agonists in Reducing the Need of Platelet Transfusion before Procedures in Chronic Liver Disease Patients
Authors: Michael Jaglal, Damian A. Laber, Ankita K. Patel, Mintallah Haider, Jennifer Eatrides, Nathan Visweshwar, Hesham Abowali
Journal: Blood (2019)
ACTR-28. A CALL FOR INCREASED ROLE OF NEUROSURGEONS IN SURGICAL TRIALS FOR NON-GLIOMATOUS PRIMARY CNS TUMORS: A SYSTEMATIC REVIEW OF THE CLINICALTRIALS.GOV DATABASE
Authors: Alireza Mansouri, Michelle Beyn, Clement Chow, Aditya Pancholi, Alexandre Boutet, Gavin Elias, Jurgen Germann, Gelareh Zadeh
Journal: Neuro-Oncology (2019)

Abstract BACKGROUND Surgery continues to be part of the mainstay of therapy for most primary CNS tumors. However, neurosurgical innovations advancing treatment options have stagnated. An understanding of past and current investigational trends is necessary to catalyze innovation in surgical trials. OBJECTIVE To evaluate the landscape of surgical clinical trials for non-diffusely infiltrating primary CNS tumors. METHODS ClinicalTrials.gov was searched on May 14th, 2019 for surgical/procedural trials based on non-diffusely infiltrating primary CNS tumors, with a focus on meningiomas, ependymomas, medulloblastomas, pituitary adenomas, vestibular scwhannomas, and chordomas. Key trial design parameters were extracted. Purely surgical interventions were classified as “technical” while fluorescence-guided and other intraoperative imaging modalities were classified as image-guided surgery. Any invasive mode of drug delivery (e.g. intra-arterial or intra-ventricular, local chemotherapy wafers, and oncolytic virus injection) was considered. RESULTS Among 944 total trial records (257 medulloblastomas, 254 ependymomas, 179 meningiomas, 156 pituitary adenomas, 56 vestibular schwannomas, and 48 chordomas) only 54 (5.7%) were procedural in nature. Ependymomas had the highest absolute number (18/254, 7%) while vestibular schwannomas had the highest percentage (6/56, 10.7%) of surgical trials. The majority of records were not randomized (41/54, 75.9%), not industry-funded (45/54, 83.3%), and were early Phase (30/54, 55.6%); there were only three Phase III trials. The relative number of new surgical trial registrations has not changed significantly over time (1990s: 5, 2000s: 19, and 2010s: 30). Approaches integrated with other disciplines, such as image-guided surgery (16/54, 29.6%) and local drug delivery (16/24, 29.6%), were among the leading categories of trials. CONCLUSIONS Despite the clinical role of surgery in management of non-diffusely infiltrating primary CNS tumors, a paucity of innovative surgical trials has been put forth. Multi-disciplinary approaches appear to be necessary for pushing the therapeutic envelope for individuals affected by these tumors, with imaging and drug development at the forefront.
Recurrent headache and facial ecchymosis: a case of dermatitis artefacta? Reply from authors
Authors: F. Garcia‐Souto, A.I. Lorente‐Lavirgen
Journal: British Journal of Dermatology (2019)

Linked Articles: Kruger. Br J Dermatol 2020; DOI: 10.1111/bjd.18691. Garcia‐Souto et al. Br J Dermatol 2019; 181:e35.
Chronic inflammation within the vascular wall in pulmonary arterial hypertension: more than a spectator
Authors: Alice Huertas, Ly Tu, Marc Humbert, Christophe Guignabert
Journal: Cardiovascular Research (2019)

This review seeks to provide an update of preclinical findings and available clinical data on the chronic persistent inflammation and its direct role on the pulmonary arterial hypertension (PAH) progression. We reviewed the different mechanisms by which the inflammatory and immune pathways contribute to the structural and functional changes occurring in the three vascular compartments: the tunica intima, tunica media, and tunica adventitia. We also discussed how these inflammatory mediator changes may serve as a biomarker of the PAH progression and summarize unanswered questions and opportunities for future studies in this area.
Bichat recommandations sur la prise en charge clinique des patients présentant une fièvre hémorragique virale lors d'un acte de bioterrorisme
Authors: P Bossi, A Tegnell, A Baka, F van Loock, J Hendriks, A Werner, H Maidhof, G Gouvras
Journal: Eurosurveillance (2004)

Les virus des fievres hemorragiques (VFH) appartiennet a divers groupes de virus, mais sont tous responsables de fievre et de troubles hemorragiques. Les VFH pouvant etre utilises comme arme biologiques sont les virus Ebola et Marburg (Filoviridae), les
CBMT-07. BIOMARKERS OF AGGRESSIVENESS IN IDH MUTANT GLIOMA
Authors: Tomohiro Yamasaki, Adrian Lita, Tyrone Dowdy, Mark Gilbert, Mioara Larion
Journal: Neuro-Oncology (2019)

Abstract BACKGROUND Gliomas with isocitrate dehydrogenase (IDH) mutations in adults evolve from lower-grade gliomas to secondary glioblastomas (GBM), a fatal disease with fast progression. IDH mutation occurs early in tumorigenesis, and persistently contribute to the reprograming of glucose, lipid and amino acid metabolism. This offer a plethora of potential biomarkers of progression. However, because it is extremely difficult to detect the distribution and transfer of metabolites changing in every moment in a single cell, the involvement of metabolites produced by mutant IDH in malignant progression remains understudied. MATERIALS AND METHODS Raman imaging spectroscopy, which can image chemical bonds and concentration of molecules at submicron spatial resolution, enables detection of spatiotemporal changes of metabolomes in live cells. We developed the software called Biomolecular Component Analysis (BCAbox) to deconvolute the recorded raw Raman spectra, leading to detection of unique spectral features of different classes of biomolecules. RESULTS AND CONCLUSIONS We applied Raman imaging spectroscopy to GBM cell lines that were transfected with IDH1 mutant gene. Our results indicated that lipid metabolism has a unique profile in IDH1 mutant gliomas. Subsequent mass spectrometry analysis of extracted organelle revealed the exact classes of lipids altered in the IDH mutant glioma and suggested biomarkers unique to IDH1 mutant. We will report our validation studies of the biomarkers in patient-derived IDH mutant glioma cell lines and patients derived-orthotopic xenograft mouse models with different degrees of aggressiveness and in matched primary versus recurrent gliomas. The results of the present study may provide novel insights into the discovery of metabolic biomarkers for the malignant progression in IDH mutant gliomas.
QOLP-24. PATIENTS’/PARENTS’ EXPERIENCES OF RECEIVING OPTUNE DELIVERED TUMOR TREATMENT FIELDS: A PEDIATRIC BRAIN TUMOR CONSORTIUM STUDY: PBTC-048
Authors: Jin-Shei Lai, Stewart Goldman, Eugene Hwang, Mehmet Kocak, Rishi Lulla, Girish Dhall, Nathan Robison, Arzu Onar-Thomas, Ira Dunkel
Journal: Neuro-Oncology (2019)

Abstract BACKGROUND Optune-delivered TTFields is a promising anti-mitotic FDA-approved cancer therapy in adult patients with high-grade gliomas (HGG), although effectiveness is not yet proven in pediatric patients. A multicenter trial [NCT03033992] evaluating the feasibility and device-related toxicity for children with recurrent or progressive supratentorial high-grade glioma (HGG) and ependymoma is being conducted. This presentation reports the interim health-related quality of life (HRQOL) and device-use experiences reported by patients and parents. METHODS Participating patients (aged 5–21 years) and one of their parents completed the following measures at baseline and prior to each intervention cycle: PROMIS Fatigue, Anger, Anxiety, Depressive Symptoms, Mobility, Upper Extremity Function, and Peer Relationships and Neuro-QOL Stigma. Participants completed an exit survey when they were off the study regarding their experiences wearing the device. RESULTS This planned interim analysis included 11 patients (7 males/4 females) with supratentorial tumors: ten HGG and one ependymoma. Median age was 14.2 (6.4–21.3) years. Patients reported worse HRQOL than the norms on all domains. Of these 11 patients, 6 completed the exit survey. No significant changes (p&lt; 0.05) between the baseline and the final assessment were found except for Stigma. Patients perceived less stigma at baseline than at the final assessment (t=2.82, p=0.0370). Of these 6 parents who completed the Exit Survey: most considered wearing the device to be easy (n=5).Patient reminders were unnecessary (n=5), patients rarely/didn’t complain (n=4) or refuse (n=5) to wear the device, there was rare/no (n=4) difficulty with daily activities because of the device, and patients were not (n=4) or sometimes (n=2) embarrassed to wear the device. CONCLUSION Preliminary results indicate Optune-delivered TTFields therapy is feasible and accepted by children and parent with no evidence of negatively impacting patients’ QOL. Accrual has been expanded beyond the interim analysis.
Bosutinib in the Real-Life Treatment of Chronic Phase Chronic Myeloid Leukemia (CML) Patients Aged &gt; 65 Years Resistant/Intolerant to Frontline Tyrosine-Kynase Inhibitors
Authors: Roberto Latagliata, Imma Attolico, Malgorzata Monika Trawinska, Isabella Capodanno, Mario Annunziata, Chiara Elena, Luigiana Luciano, Monica Crugnola, Micaela Bergamaschi, Massimiliano Bonifacio, Claudia Baratè, Endri Mauro, Gianni Binotto, Nicola Sgherza, Chiara Aguzzi, Barbara Monteleone, Federica Sorà, Giovanni Caocci, Debora Luzi, Elena Mariggiò, Luigi Scaffidi, Daniele Cattaneo, Antonella Gozzini, Ambra Di veroli, Sara Galimberti, Alessandra Iurlo, Massimo Breccia, Giorgina Specchia
Journal: Blood (2019)
Ramp-up Treatment Strategy in Philadelphia Positive Acute Lymphoblastic Leukemia Is Associated with Deep Molecular Remissions and Favorable Outcomes
Authors: Nabiel A. Mir, Charles Bodine, Denise Peker, Kimo Bachiashvili, Pankit Vachhani, Luciano J. Costa, Harry P. Erba, Nikolaos Papadantonakis
Journal: Blood (2019)
Effect of lung recruitment maneuver on oxygenation, physiological parameters and mortality in acute respiratory distress syndrome patients: a systematic review and meta-analysis
Authors: Joris Pensier, Audrey de Jong, Zied Hajjej, Nicolas Molinari, Julie Carr, Fouad Belafia, Gérald Chanques, Emmanuel Futier, Elie Azoulay, Samir Jaber
Journal: Intensive Care Medicine (2019)
Activated leukocyte cell adhesion molecule regulates B lymphocyte migration across central nervous system barriers
Authors: Laure Michel, Camille Grasmuck, Marc Charabati, Marc-André Lécuyer, Stephanie Zandee, Tessa Dhaeze, Jorge I. Alvarez, Rui Li, Sandra Larouche, Lyne Bourbonnière, Robert Moumdjian, Alain Bouthillier, Boaz Lahav, Pierre Duquette, Amit Bar-Or, Jennifer L. Gommerman, Evelyn Peelen, Alexandre Prat
Journal: Science Translational Medicine (2019)

Activated leukocyte cell adhesion molecule mediates B lymphocyte migration across central nervous system barriers.